EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer
Khan SA, Zeng Z, Shia J, Paty PB. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathology & Oncology Research 2016, 23: 673-677. PMID: 28025786, PMCID: PMC5451302, DOI: 10.1007/s12253-016-0166-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorCamptothecinCetuximabColorectal NeoplasmsDNA Mutational AnalysisErbB ReceptorsFemaleGene AmplificationGenes, p53HumansIrinotecanMaleMiddle AgedMutationRas ProteinsConceptsCombination biologic therapyMetastatic colorectal cancerIrinotecan-refractory colorectal cancerRefractory colorectal cancerColorectal cancerEGFR gene amplificationBiologic therapyKRAS mutationsIrinotecan-refractory metastatic colorectal cancerRefractory metastatic colorectal cancerCombination Targeted TherapyGene amplificationPhase II trialEGFR copy numberII trialPredictive biomarkersPredictive markerTargeted therapyTreatment responseBRAF mutationsBevacizumabPatientsCetuximabTumor tissueTherapy